PDS Biotech regains Nasdaq minimum bid price compliance as of June 2, 2026

PDS Biotechnology Corp

Nasdaq notified PDS Biotech on June 2, 2026 that it regained compliance with the $1.00 minimum bid price rule.
The company had fallen below $1.00 for 30 consecutive business days, triggering a deficiency letter on Feb 25, 2026.
Nasdaq has closed the matter; no further compliance actions required for this issue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.